NASDAQ:SAVACassava Sciences Stock Price, Forecast & News

Cassava Sciences' stock was trading at $4.24 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, SAVA stock has decreased by 26.3% and is now trading at $3.1250. View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cassava Sciences in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Cassava Sciences.

Cassava Sciences is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Cassava Sciences.

Cassava Sciences Inc (NASDAQ:SAVA) posted its quarterly earnings data on Wednesday, May, 6th. The company reported ($0.05) earnings per share (EPS) for the quarter. View Cassava Sciences' earnings history.

Shares of Cassava Sciences reverse split on the morning of Wednesday, May 10th 2017. The 1-7 reverse split was announced on Monday, May 8th 2017. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 9th 2017. An investor that had 100 shares of Cassava Sciences stock prior to the reverse split would have 14 shares after the split.

2 brokerages have issued 1-year target prices for Cassava Sciences' shares. Their forecasts range from $12.00 to $16.00. On average, they anticipate Cassava Sciences' share price to reach $14.00 in the next year. This suggests a possible upside of 348.0% from the stock's current price. View analysts' price targets for Cassava Sciences.

Media headlines about SAVA stock have trended negative this week, InfoTrie Sentiment reports. The research group scores the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cassava Sciences earned a coverage optimism score of -2.1 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news about Cassava Sciences.

Some companies that are related to Cassava Sciences include Liminal BioSciences (LMNL), Pivot Pharmaceuticals (PVOTF), Concert Pharmaceuticals (CNCE), Menlo Therapeutics (MNLO), Avadel Pharmaceuticals (AVDL), Abeona Therapeutics (ABEO), Spero Therapeutics (SPRO), OrganiGram (OGI), Bicycle Therapeutics (BCYC), IDEAYA Biosciences (IDYA), AMAG Pharmaceuticals (AMAG), Lannett (LCI), ProQR Therapeutics (PRQR), IVERIC bio (ISEE) and Northwest Biotherapeutics (NWBO). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cassava Sciences investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), DURECT (DRRX), Bristol-Myers Squibb (BMY), Synergy Pharmaceuticals (SGYP), Baidu (BIDU), Exelixis (EXEL), Novavax (NVAX) and Opko Health (OPK).

Cassava Sciences trades on the NASDAQ under the ticker symbol "SAVA."

Shares of SAVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of SAVA stock can currently be purchased for approximately $3.13.

Cassava Sciences has a market capitalization of $77.44 million. The company earns $-4,630,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis. Cassava Sciences employs 9 workers across the globe.

The official website for Cassava Sciences is www.cassavasciences.com.

Cassava Sciences' mailing address is 7801 N CAPITAL OF TEXAS HIGHWAY SUITE 260, AUSTIN TX, 78731. The company can be reached via phone at 512-501-2444 or via email at [email protected]